Agendia Inc, Irvine, Calif, and Bluebee, Rijswijk, the Netherlands, have partnered to provide a secure data processing solution for Agendia’s MammaPrint BluePrint breast cancer recurrence and molecular subtyping kit, which is intended for prognostic use in a clinical setting.
Initially available in Europe, the next-generation sequencing (NGS)-based MammaPrint BluePrint kit will enable cancer centers to run the test in-house. The partnership with Bluebee enables secure global access to test results, while ensuring all data complies with local data privacy and residency regulations, an essential development in preparation for the system’s European launch in early 2018.
The MammaPrint test analyzes 70 genes most associated with breast cancer recurrence to provide a binary low or high risk-of-cancer-recurrence result, while the BluePrint test analyzes 80 genes to classify breast cancer into four functional molecular subtypes. The combined MammaPrint BluePrint kit will help physicians personalize treatment management by identifying women who are at a low genomic risk for disease recurrence and unlikely to benefit from chemotherapy.
“The launch of the NGS-based MammaPrint BluePrint kit will bring our breast cancer tests to cancer centers across Europe, ensuring that even more patients and their physicians can benefit from the test,” says Marjolaine Baldo, PhD, Agendia’s commercial vice president for Europe, the Middle East, and Africa. “Therefore, when choosing a data processing partner, it was important for us to work with a team that could deliver these results in a highly secure form. We are very pleased to partner with Bluebee as we finalize the development of the MammaPrint BluePrint kit ahead of European launch.”
“Through this partnership, Bluebee enables Agendia to make the data tangible and actionable,” says Hans Cobben, chief executive of Bluebee. “We are generating real clinical solutions out of science, improving human healthcare and enabling a truly individualized approach. This will take the fight against breast cancer to a new level.”